BRAF mutations, present in ∼40%–50% of common cutaneous melanomas,17 are detected in ∼20% AM18,19,20 and are largely absent in MM21,22; thus, only a minority of these patients are suitable for treatment with BRAF&MEK targeting agents. This evidence concerns the gene BRAF and cutaneous melanoma.